Bio-Techne Corporation

NASDAQ:TECH

Biotechnology

Healthcare
$72.75 -1.84%

-$1.03 today

Market cap
$11.43B
Beta
1.36
P/E (TTM)
78.3
EPS (TTM)
$0.70
Dividend yield
0.58%
52W Low $43.20High $72.16

Volume 2.63M

Average 2.66M

TECH EBITDA Margin

EBITDA as a percentage of revenue.

Bio-Techne CorporationNASDAQ: TECH

EBITDA Margin · Q1 FY2027 · quarter ended Sep 2026

EBITDA Margin narrows to 20.2%

EBITDA Margin was 20.2% in Q1 FY2027, down 6.0 pp from a year earlier. On a trailing-twelve-month basis it was 26.8%, up 8.6 pp year over year. Over 3 fiscal years it narrowed by 11.9 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 7 analysts of 38.3% for the fiscal year ending Jun 2027, up from 28.3% in FY2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
20.2%-8.4 pp QoQ
Last fiscal yearJun 2026
28.3%+10.5 pp YoY
LTMSep 2026
26.8%+8.6 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-6.0 pp+10.5 pp+16.5 pp
1 year+10.5 pp+10.0 pp-0.5 pp
3 years-11.9 pp+6.1 pp+18.0 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2026
28.3%
Year-over-year change
+10.5pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How TECH compares with its peers on the latest reported figures

  • TECH's LTM Sep 2026 EBITDA Margin of 26.8% is the 4th highest of the 11 companies compared; the peer median is 21.8%.
  • Its year-over-year change of +8.6 pp is the 3rd highest of 10, against a peer median of -1.6 pp.
  • Over three fiscal years its change of -11.9 pp compares with a peer median of -1.4 pp.
TECH Competitors Peer median
EBITDA Margin for TECH and competitors
Company Period LTM level YoY 3-year change
QGENQiagen N.V.LTM Jun 202633.5% -1.6 pp-2.1 pp
DHRDanaher CorporationLTM Sep 202627.7% -0.6 pp-7.3 pp
AAgilent Technologies, Inc.LTM Jul 202627.6% +1.1 pp-1.4 pp
TECHBio-Techne CorporationLTM Sep 202626.8% +8.6 pp-11.9 pp
RVTYRevvity, Inc.LTM Jul 202626.3% -3.0 pp-8.9 pp
TMOThermo Fisher Scientific Inc.LTM Sep 202623.7% -2.2 pp-0.9 pp
BIOBio-Rad Laboratories, Inc.LTM Jun 202619.9% -6.2 pp+208.5 pp
BRKRBruker CorporationLTM Jun 20267.1% -4.6 pp-11.7 pp
TXG10x Genomics, Inc.LTM Sep 20266.1% +10.9 pp+25.5 pp
ALMRAlamar Biosciences, Inc.FY2025-33.5% ——
SEERSeer, Inc.LTM Mar 2026-427.9% +95.5 pp+175.4 pp
Peer median (excluding TECH) 21.8%-1.6 pp-1.4 pp

Competitors are the stored peer set for TECH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
FY2026
Jun 2026
Revenue1.11B1.14B1.16B1.22B1.22B
Cost of Revenue349.1M366.89M389.34M429.36M415.97M
Gross Profit756.5M769.82M769.73M790.27M799.07M
Gross Margin68.4%67.7%66.4%64.8%65.8%
Research & Development87.14M92.49M96.66M99.5M94.77M
Selling, General & Admin339M352.44M393.32M415.1M452.42M
Operating Expenses459.91M470.87M563.04M688.02M547.18M
Depreciation & Amortization101.07M107.24M111.71M109.9M97.36M
EBITDA413.76M457.11M313.14M216.88M343.44M
EBITDA Margin37.4%40.2%27.0%17.8%28.3%
Operating Income296.59M298.94M206.69M102.26M251.89M
Operating Margin26.8%26.3%17.8%8.4%20.7%
Interest Income794K3.41M3.32M3.89M0
Interest Expense11.31M11.22M15.74M8.51M5.41M
Other Income / Expenses4.8M39.72M(21M)(3.79M)(11.21M)
Income Before Tax301.39M338.66M185.69M98.46M240.68M
Pre-Tax Margin27.3%29.8%16.0%8.1%19.8%
Income Tax Expense38.29M53.22M17.58M25.06M58.82M
Net Income272.05M285.26M168.11M73.4M181.86M
Net Margin24.6%25.1%14.5%6.0%15.0%
EPS (Basic)1.731.811.070.471.17
EPS (Diluted)1.661.761.050.461.16
Weighted Avg Shares156.88M157.18M157.71M157.52M155.96M
Weighted Avg Shares (Diluted)164.12M161.86M160.77M159.72M157.01M

Bio-Techne Corporation

NASDAQ:TECH

Intrinsic Alpha fair value

Locked

Current Price

$72.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.